Skip to main content
Erschienen in: World Journal of Urology 2/2014

01.04.2014 | Topic Paper

Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy

verfasst von: Pierre Colin, Tarek P. Ghoneim, Laurent Nison, Thomas Seisen, Eric Lechevallier, Xavier Cathelineau, Adil Ouzzane, Marc Zerbib, Jean-Alexandre Long, Alain Ruffion, Sébastien Crouzet, Olivier Cussenot, Marie Audouin, Jacques Irani, Solène Gardic, Pascal Gres, François Audenet, Mathieu Roumiguié, Antoine Valeri, Morgan Rouprêt

Erschienen in: World Journal of Urology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the risk factors of metastasis relapse in pT2-3 upper tract urothelial carcinomas (UTUCs) treated by radical nephroureterectomy (RNU) without lymphadenectomy (LN).

Methods

A multicentric retrospective study was performed for pT2-3 pNx UTUCs treated by RNU between 1995 and 2010. The following criteria were retrieved: age, gender, American Society of Anaesthesiologists physical status, surgical approach, preoperative hydronephrosis, stage, grade, tumor location, surgical margin, lymphovascular invasion (LVI) status and outcomes. Metastasis-free survival (MFS) was measured by Kaplan–Meier method with the log-rank test.

Results

Overall, 151 patients were included. The median follow-up was 18.5 months (IQR 9.5–37.9). The 2- and 5-year MFS were 69 % ± 4.5 and 54.1 % ± 5.8, respectively. In univariate analysis, ureteral location, pT3 stage, positive LVI status and positive surgical margin were significantly associated with worse MFS (p = 0.03; 0.02; 0.01 and 0.006, respectively). In the multivariate analysis of ureteral location and pT3 stage were independent prognostic factors (p = 0.03 and 0.03, respectively). Based on the results of the univariate analysis, we proposed a risk model predicting MFS, which classifies patients into 3 categories with different overall survival (p < 0.001).

Conclusion

In view of our data, tumor location, T stage, LVI and surgical margin status are mandatory to predict survival in case of RN without LN. Contingent upon external validation, our risk model based on these variables could be useful to provide relevant information concerning metastasis relapse probability and necessity of close follow-up for these patients.
Literatur
1.
Zurück zum Zitat Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J et al (2009) Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 104:1436–1440PubMedCrossRef Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J et al (2009) Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 104:1436–1440PubMedCrossRef
2.
Zurück zum Zitat Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M et al (2013) European guidelines on upper urinary tract urothelial carcinomas: 2013 update. Eur Urol 63:1059–1071PubMedCrossRef Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M et al (2013) European guidelines on upper urinary tract urothelial carcinomas: 2013 update. Eur Urol 63:1059–1071PubMedCrossRef
3.
Zurück zum Zitat Ouzzane A, Colin P, Ghoneim TP, Zerbib M, De La Taille A, Audenet F et al (2013) The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World J Urol 31:189–197PubMedCrossRef Ouzzane A, Colin P, Ghoneim TP, Zerbib M, De La Taille A, Audenet F et al (2013) The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World J Urol 31:189–197PubMedCrossRef
4.
Zurück zum Zitat Roupret M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR et al (2013) Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized post-operative nomogram using decision curve analysis. J Urol 189:1662–1669PubMedCrossRef Roupret M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR et al (2013) Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized post-operative nomogram using decision curve analysis. J Urol 189:1662–1669PubMedCrossRef
5.
Zurück zum Zitat Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen N et al (2012) The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology 79:840–845PubMedCrossRef Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen N et al (2012) The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology 79:840–845PubMedCrossRef
6.
Zurück zum Zitat Roscigno M, Shariat SF, Freschi M, Margulis V, Karakiewizc P, Suardi N et al (2009) Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology 74:1070–1074PubMedCrossRef Roscigno M, Shariat SF, Freschi M, Margulis V, Karakiewizc P, Suardi N et al (2009) Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology 74:1070–1074PubMedCrossRef
7.
Zurück zum Zitat Abe T, Shinohara N, Muranaka M, Sazawa A, Maruyama S, Osawa T et al (2010) Role of lymph node dissection in the treatment of urothelial carcinoma of the upper urinary tract: multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes. Eur J Surg Oncol 36:1085–1091PubMedCrossRef Abe T, Shinohara N, Muranaka M, Sazawa A, Maruyama S, Osawa T et al (2010) Role of lymph node dissection in the treatment of urothelial carcinoma of the upper urinary tract: multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes. Eur J Surg Oncol 36:1085–1091PubMedCrossRef
8.
Zurück zum Zitat Ariane MM, Colin P, Ouzzane A, Pignot G, Audouin M, Cornu JN et al (2011) Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 19:301–308PubMedCrossRef Ariane MM, Colin P, Ouzzane A, Pignot G, Audouin M, Cornu JN et al (2011) Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 19:301–308PubMedCrossRef
9.
Zurück zum Zitat Sobin L, Godspodarowicz M, Wittekind C (2009) Renal pelvis and ureter: TNM classification of malignant tumours. Urological tumours. International Union against Cancer. Wiley-Blackwell, New York, pp 258–261 Sobin L, Godspodarowicz M, Wittekind C (2009) Renal pelvis and ureter: TNM classification of malignant tumours. Urological tumours. International Union against Cancer. Wiley-Blackwell, New York, pp 258–261
10.
Zurück zum Zitat Mostofi FK, Sorbin LH and Torloni H (1973) International histological classification of tumours: histological typing of urinary bladder tumours, World Health Organization, New York Mostofi FK, Sorbin LH and Torloni H (1973) International histological classification of tumours: histological typing of urinary bladder tumours, World Health Organization, New York
11.
Zurück zum Zitat Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ et al (2009) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57:1064–1071CrossRef Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ et al (2009) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57:1064–1071CrossRef
12.
Zurück zum Zitat Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618PubMedCentralPubMedCrossRef Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y et al (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Colin P, Ouzzane A, Yates DR, Audenet F, Pignot G, Arvin-Berod A et al (2012) Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol 19:3613–3620PubMedCrossRef Colin P, Ouzzane A, Yates DR, Audenet F, Pignot G, Arvin-Berod A et al (2012) Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival. Ann Surg Oncol 19:3613–3620PubMedCrossRef
14.
Zurück zum Zitat Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F et al (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265PubMedCrossRef Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F et al (2011) Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol 60:1258–1265PubMedCrossRef
15.
Zurück zum Zitat Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K et al (2009) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079PubMedCrossRef Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K et al (2009) Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 57:1072–1079PubMedCrossRef
16.
Zurück zum Zitat Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G et al (2009) Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 182:2177–2181PubMedCrossRef Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G et al (2009) Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J Urol 182:2177–2181PubMedCrossRef
17.
Zurück zum Zitat Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS et al (2011) The Impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253PubMedCrossRef Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS et al (2011) The Impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61:245–253PubMedCrossRef
18.
Zurück zum Zitat Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ et al (2011) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13PubMedCrossRef Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ et al (2011) Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int 110:E7–E13PubMedCrossRef
19.
Zurück zum Zitat Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52:594–601PubMedCrossRef Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52:594–601PubMedCrossRef
20.
Zurück zum Zitat Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G et al (2013) Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. J Urol 189:468–473PubMedCrossRef Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G et al (2013) Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. J Urol 189:468–473PubMedCrossRef
21.
Zurück zum Zitat Birtle AJ, Lewis R, Johnson M, Hall E (2012) Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC)—opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) trial. BJU Int 110:919–921PubMedCrossRef Birtle AJ, Lewis R, Johnson M, Hall E (2012) Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC)—opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) trial. BJU Int 110:919–921PubMedCrossRef
22.
Zurück zum Zitat Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP (2011) Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78:61–67PubMedCentralPubMedCrossRef Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP (2011) Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78:61–67PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R et al (2011) Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 108:1286–1291PubMedCrossRef Youssef RF, Shariat SF, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R et al (2011) Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 108:1286–1291PubMedCrossRef
Metadaten
Titel
Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy
verfasst von
Pierre Colin
Tarek P. Ghoneim
Laurent Nison
Thomas Seisen
Eric Lechevallier
Xavier Cathelineau
Adil Ouzzane
Marc Zerbib
Jean-Alexandre Long
Alain Ruffion
Sébastien Crouzet
Olivier Cussenot
Marie Audouin
Jacques Irani
Solène Gardic
Pascal Gres
François Audenet
Mathieu Roumiguié
Antoine Valeri
Morgan Rouprêt
Publikationsdatum
01.04.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 2/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-013-1116-1

Weitere Artikel der Ausgabe 2/2014

World Journal of Urology 2/2014 Zur Ausgabe

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.